3. Spinal muscular atrophy Clinical trials / Disease details

Clinical trials : 237 / Drugs : 123 - (DrugBank : 29) / Drug target genes : 51 - Drug target pathways : 75

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00481013 (ClinicalTrials.gov)	July 2007	30/5/2007	Valproic Acid in Ambulant Adults With Spinal Muscular Atrophy	Prospective Controlled Trial of Valproic Acid in Ambulant Adults With Spinal Muscular Atrophy (VALIANTSMA) Study	Spinal Muscular Atrophy	Drug: Valproic Acid (VPA);Drug: Placebo	University of Utah	Families of Spinal Muscular Atrophy;Abbott	Completed	18 Years	60 Years	Both	33	Phase 2	United States
2	NCT00374075 (ClinicalTrials.gov)	September 2003	6/9/2006	Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy	In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy	Spinal Muscular Atrophy	Drug: Valproic Acid	University of Utah	Families of Spinal Muscular Atrophy;Sigma Tau Pharmaceuticals, Inc.;Abbott	Completed	2 Years	N/A	Both	42	Phase 1	United States